Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | FOLH1 | Q04609 | 10/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | LAP3 | P28838 | 3/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.47 |
| ▸ | PLA2G5 | P39877 | 2/20 | 0.47 |
| ▸ | GRN | P28799 | 1/20 | 0.47 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL628966 | 1.00 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL3447885 | 1.00 | ALDH1A1 (0.64) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL23964665 | 0.84 | FOLH1 (0.64) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL27337953 | 0.84 | FOLH1 (0.64) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL13147590 | 0.84 | LAP3 (0.51) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL3841242 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL27134001 | 0.83 | ALDH1A1 (0.55) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL12500677 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL12661064 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MEN1LMNAKMT2AFOLH1 | |
| SCHEMBL8536002 | 0.83 | ALDH1A1 (0.48) | ALDH1A1MEN1LMNAKMT2AFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-11827586-B2 | Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2023-11-28 | — | — | US | disclosed |
| US-20210253517-A1 | METHOD FOR PRODUCING AMINO ACID AMINOALKYL ESTER OR INORGANIC ACID SALT THEREOF | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-08-19 | — | — | US | disclosed |
| US-9758487-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | JANSSEN SCIENCES IRELAND UC (IE) | 2016-11-24 | — | — | US | disclosed |
| US-9433609-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-09-06 | — | — | US | disclosed |
| US-9427428-B2 | Benzimidazole-imidazole derivatives | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-9284270-B2 | Boronic acid catalysts and methods of use thereof for activation and transformation of carboxylic acids | THE GOVERNERS OF THE UNIVERSITY OF ALBERTA (CA) | 2016-03-15 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-9227961-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-01-05 | — | — | US | disclosed |
| WO-2010091413-A1 | LINKED DIBENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | disclosed |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-28 | — | — | US | disclosed |
| CN-1341593-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1341592-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1341590-A | Proteinase inhibitor | SMITHKLINE BEECHEM CORP (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1261276-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 2000-07-26 | — | — | CN | disclosed |
| CN-1207095-A | Protease inhibitors | SMITHKLINE BEECHAM CORP (US) | 1999-02-03 | — | — | CN | disclosed |
| US-5523463-A | Method of producing halogenated and alpha-aminoalchohols | HOFFMANN-LA ROCHE INC. (US) | 1996-06-04 | — | — | US | disclosed |
| EP-0381997-A1 | Microbially prepared N-acetyl-2,3-didehydroleucine acylase, process for its preparation and its use | Degussa Aktiengesellschaft (DE) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253517-A1 | METHOD FOR PRODUCING AMINO ACID AMINOALKYL ESTER OR INORGANIC ACID SALT THEREOF | SLC6A15, SLC6A19, ALAD | ALDH1A1 1123/4885MEN1 2569/4885LMNA 4460/4885 |
| US-20080050336-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885MEN1 4867/4885LMNA 3159/4885 |
| US-20160340344-A1 | BENZIMIDAZOLE-IMIDAZOLE DERIVATIVES | HAVCR2, CBR3, ZC3HAV1 | ALDH1A1 1349/4885MEN1 4654/4885LMNA 4586/4885 |
| US-20100158862-A1 | Hepatitis C Virus Inhibitors | HAVCR2, PYGL, HCCS | ALDH1A1 1144/4885MEN1 4867/4885LMNA 3159/4885 |
| US-11827586-B2 | Method for producing amino acid aminoalkyl ester or inorganic acid salt thereof | SLC6A15, SLC6A19, ALAD | ALDH1A1 1123/4885MEN1 2569/4885LMNA 4460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.